$265.87
▼ -1.7% Today
as of Sep 4, 16:46 ET
Last 30 days
Recent Press Releases & News
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing
Oppenheimer Adjusts Price Target on Ascendis Pharma to $312 From $304, Maintains Outperform Rating
Overview
52-week range
$186
$282
83% of range
Avg surprise (last 3)
+26.8%
Avg reaction (last 2)
+1.3%
50% positive
Latest IV / EM
38%
EM ±6.0% · $270 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $0.32 | $0.21 | +52.4% | +119.3% | +4.3% | earnings |
| Thu Aug 7, 2025 | Jun/2025 | $-0.93 | $-1.42 | +34.5% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-1.66 | $-1.56 | -6.4% | — | -1.7% | earnings |